Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shionogi-co-ltd" target="_blank" data-smartkarma-citation="entities:19535:1" rel="noopener">Shionogi &amp; Co (4507 JP)</a> announced Q1FY27 result, with revenue and all profit categories achieving record-high for the first quarter, driven by existing businesses and integration effects from acquired businesses.</li>
<li>Progress rate of key parameters of Q1FY27 against H1FY27 guidance is strong, thereby enhancing our conviction on the company meeting guidance.</li>
<li>Addition of growth drivers in multiple QOL diseases that are not affected by fluctuations in infectious disease outbreaks, together with contributions from acquired products should lead to accelerated profitable growth.</li>
</ul>



Shionogi &amp; Co (4507 JP) announced Q1FY27 result, with revenue and all profit categories achieving record-high for the first quarter, driven by existing businesses and integration effects from acquired businesses.
Progress rate of key parameters of Q1FY27 against H1FY27 guidance is strong, thereby enhancing our conviction on the company meeting guidance.
Addition of growth drivers in multiple QOL diseases that are not affected by fluctuations in infectious disease outbreaks, together with contributions from acquired products should lead to accelerated profitable growth.


Shionogi & Co (4507 JP): Strong Start to FY27 as Business Diversification Is Yielding Result

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Index Rebalance

<ul>
<li>The September 2026 Nikkei 225 Review was announced today. Results are discussed in <a href="https://www.smartkarma.com/insights/quiddity-index-nikkei-225-sep26-rebal-results-3-adds-3-dels-no-new-rules-impact" target="_blank" data-smartkarma-citation="insights:266702" rel="noopener">[Quiddity Index] Nikkei 225 Sep26 Rebal Results: 3 ADDs, 3 DELs, No New Rules Impact</a>. </li>
<li>Things went roughly as predicted for the selection of data they chose (there was a question about industry categorisation). Some people questioned discretionary ordering. That's settled. </li>
<li>With 92% of the Mar27 rebal data period behind us, we take a brief look at what the March 2027 rebal. It's kind of confusing. The third delete is tough. </li>
</ul>


The September 2026 Nikkei 225 Review was announced today. Results are discussed in [Quiddity Index] Nikkei 225 Sep26 Rebal Results: 3 ADDs, 3 DELs, No New Rules Impact. 
Things went roughly as predicted for the selection of data they chose (there was a question about industry categorisation). Some people questioned discretionary ordering. That's settled. 
With 92% of the Mar27 rebal data period behind us, we take a brief look at what the March 2027 rebal. It's kind of confusing. The third delete is tough. 


[Quiddity Index] Advance Look at March 2027 Nikkei 225 Rebal Predictions - The 3rd DELETE Is Tough

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

<ul>
<li>The review period for the <a href="https://www.smartkarma.com/entities/nikkei-225" target="_blank" data-smartkarma-citation="entities:22909:1" rel="noopener">Nikkei 225 (NKY INDEX)</a> September rebalance ended on 31 July. Nikkei has also confirmed <a href="https://www.smartkarma.com/entities/advantest-corp" target="_blank" data-smartkarma-citation="entities:18107:1" rel="noopener">Advantest Corp (6857 JP)</a>'s capping at the rebalance.</li>
<li>The newly created Information &amp; Communication sector is the most underweight while the Technology sector remains the most overweight. We could see some changes from these sectors.</li>
<li>The changes at the September rebalance will set the tone for future rebalances and sector balance is likely to play a large role moving forward.</li>
</ul>


The review period for the Nikkei 225 (NKY INDEX) September rebalance ended on 31 July. Nikkei has also confirmed Advantest Corp (6857 JP)'s capping at the rebalance.
The newly created Information &amp; Communication sector is the most underweight while the Technology sector remains the most overweight. We could see some changes from these sectors.
The changes at the September rebalance will set the tone for future rebalances and sector balance is likely to play a large role moving forward.


Nikkei 225 Index Rebalance Preview (Sep 2026): Potential Adds, Deletes, Capping & Other Changes

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

EURO STOXX 50 Price EUR / Technical Analysis

<ul>
<li>Key support levels on global equity indexes (EURO STOXX 50, $ACWX, $EFA) are beginning to break as the U.S. dollar (DXY) and 10-year Treasury yield break above $105.70 and 4.35%.</li>
<li>This significantly increases the odds of a break below major $92-$93 support on $ACWI, and we would shift to a more cautious outlook only on a break below $92.</li>
<li>We shifted to overweight value within non-U.S. equities last week, and we are now also shifting to overweight small-caps within non-U.S. equities as well. Buys in Transportation, Communications, and HealthCare</li>
</ul>


Key support levels on global equity indexes (EURO STOXX 50, $ACWX, $EFA) are beginning to break as the U.S. dollar (DXY) and 10-year Treasury yield break above $105.70 and 4.35%.
This significantly increases the odds of a break below major $92-$93 support on $ACWI, and we would shift to a more cautious outlook only on a break below $92.
We shifted to overweight value within non-U.S. equities last week, and we are now also shifting to overweight small-caps within non-U.S. equities as well. Buys in Transportation, Communications, and HealthCare


Supports Starting to Break; Upgrading Non-U.S. Small-Caps to Overweight; Transports/Comm/HC Buys

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sumitomo-pharma-co" target="_blank" data-smartkarma-citation="entities:1935:1" rel="noopener">Sumitomo Pharma (4506 JP)</a> revenue was up 20% YoY to ¥129.5B in Q1FY27 on the back of continued strong sales in North America (up 35% YoY to ¥94.3B).</li>
<li>Orgovyx (revenue jumped 58% YoY to ¥51.6B) witnessed solid patient growth in medicare patients while Gemtesa (revenue rose 42% to ¥30.2B) improved market share through clinical differentiation.</li>
<li>Company reiterated FY27 guidance. Core drugs will hold fort and eventually Enzomenib &amp; Amchepry is expected to follow suit in near to medium term.</li>
</ul>



Sumitomo Pharma (4506 JP) revenue was up 20% YoY to ¥129.5B in Q1FY27 on the back of continued strong sales in North America (up 35% YoY to ¥94.3B).
Orgovyx (revenue jumped 58% YoY to ¥51.6B) witnessed solid patient growth in medicare patients while Gemtesa (revenue rose 42% to ¥30.2B) improved market share through clinical differentiation.
Company reiterated FY27 guidance. Core drugs will hold fort and eventually Enzomenib &amp; Amchepry is expected to follow suit in near to medium term.


Sumitomo Pharma (4506 JP): North America Continue To Be Robust in Q1FY27, Enzomenib Progressing Well

Japan

ONO PHARMACEUTICAL CO., LTD. manufactures and sells pharmaceutical products. The Company mainly researches and develops prescription drugs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ono Pharmaceutical (4528 JT)

Shionogi & Co (4507 JP): Strong Start to FY27 as Business Diversification Is Yielding Result

Shionogi announced Q1FY27 result, with revenue and all profit categories achieving record-high for the first quarter, driven by existing businesses...

Tina Banerjee

[Quiddity Index] Advance Look at March 2027 Nikkei 225 Rebal Predictions - The 3rd DELETE Is Tough

The Sep26 Nikkei 225 results are announced. That means we can have a pretty good look at what happens in March 2027 (though the choice of Capcom vs...

Travis Lundy

Nikkei 225 Index Rebalance Preview (Sep 2026): Potential Adds, Deletes, Capping & Other Changes

We forecast 3 changes for the NKY in Sep and highlight potential changes. The introduction of a new sector and a new rule changes things a bit and...

Brian Freitas

Supports Starting to Break; Upgrading Non-U.S. Small-Caps to Overweight; Transports/Comm/HC Buys

Support levels on global indexes (EURO STOXX 50, $ACWX, $EFA) beginning to break as $DXY and 10-year Treasury yield $TNX break above $105.70 and...

Vermilion Research

Sumitomo Pharma (4506 JP): North America Continue To Be Robust in Q1FY27, Enzomenib Progressing Well

Sumitomo Pharma's Q1FY27 revenue rose 20% YoY to ¥129.5B, driven by strong sales in North America. Orgovyx and Gemtesa saw significant revenue...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Shionogi & Co (4507 JP): Strong Start to FY27 as Business Diversification Is Yielding Result

Shionogi announced Q1FY27 result, with revenue and all profit categories achieving record-high for the first quarter, driven by existing businesses...

Tina Banerjee

[Quiddity Index] Advance Look at March 2027 Nikkei 225 Rebal Predictions - The 3rd DELETE Is Tough

The Sep26 Nikkei 225 results are announced. That means we can have a pretty good look at what happens in March 2027 (though the choice of Capcom vs...

Travis Lundy

Nikkei 225 Index Rebalance Preview (Sep 2026): Potential Adds, Deletes, Capping & Other Changes

We forecast 3 changes for the NKY in Sep and highlight potential changes. The introduction of a new sector and a new rule changes things a bit and...

Brian Freitas

Supports Starting to Break; Upgrading Non-U.S. Small-Caps to Overweight; Transports/Comm/HC Buys

Support levels on global indexes (EURO STOXX 50, $ACWX, $EFA) beginning to break as $DXY and 10-year Treasury yield $TNX break above $105.70 and...

Vermilion Research

Sumitomo Pharma (4506 JP): North America Continue To Be Robust in Q1FY27, Enzomenib Progressing Well

​Sumitomo Pharma's Q1FY27 revenue rose 20% YoY to ¥129.5B, driven by strong sales in North America. Orgovyx and Gemtesa saw significant revenue...

Tina Banerjee

Sumitomo Pharma's Q1FY27 revenue rose 20% YoY to ¥129.5B, driven by strong sales in North America. Orgovyx and Gemtesa saw significant revenue...